Business
    Next Score View the next score

    Mass. Movers

    Firm sets a $22 price target for Verastem

    Verastem’s cancer research focuses on stem cells.
    Kayana Szymczak for the Globe/File
    Verastem’s cancer research focuses on stem cells.

    Analysts at Cantor Fitzgerald began coverage of Cambridge-based Verastem Inc. with a “buy” rating and a $22 price target. Verastem is developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis, according to the company. Verastem is developing small-molecule inhibitors of signaling pathways that are critical to cancer stem cell survival.

    Advertisement